The New England Journal of Medicine earlier this month.“The emerging data appear inconsistent with more robust evidence from multiple randomized, controlled studies published in peer-reviewed journals validating the clinical benefit of Veklury (remdesivir).
We are concerned that the data from this open-label global trial have not undergone the rigorous review required to allow for constructive scientific discussion, particularly given the limitations of the trial design," Gilead said in a statement on Friday.The WHO trial was an open-label trial, in which 11,266 adults from 30 were randomized, with 2,750 allocated remdesivir, 954 hydroxychloroquine, 1,411 lopinavir, 651 interferon and lopinavir, 1,412 only Interferon, and 4,088 no study.